ArticleCancer science2021

MK-6, a novel not-α IL-2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance.

Maki Kobayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.